ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) dropped 3.8% during mid-day trading on Monday . The company traded as low as C$5.98 and last traded at C$6.00. Approximately 19,701 shares were traded during trading, an increase of 492% from the average daily volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Price Performance
The company has a debt-to-equity ratio of 108.33, a current ratio of 0.51 and a quick ratio of 1.30. The company’s fifty day moving average is C$6.00. The company has a market capitalization of C$51.48 million, a PE ratio of -1.78 and a beta of 1.19.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Recommended Stories
- Five stocks we like better than ProMIS Neurosciences
- Trading Halts Explained
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- What is a Dividend King?
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Roth IRA Calculator: Calculate Your Potential Returns
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
